bioMerieux, Inc.: FDA filings under this applicant name

FDA lists 261 510(k) clearances under 6 spellings of the applicant name “bioMerieux, Inc.” (first 1983, latest 2026), plus 3 PMA and 1 De Novo decisions, across 48 product codes in 5 review panels. Median 510(k) review time under this name: 60 days. Since 2017 the median was 92 days, against 90 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.

Caduvo groups this applicant name under bioMérieux, based on public ownership records.

510(k) clearances per year

YearClearancesMedian review days
201212206
20136182
20143232
20151434
20167227
20171590
20183160
2019984
2020467
20215268
20228189
2023894
20244175
2025390
2026795

Review time against the same product codes

Since 2017, 510(k)s cleared under the name bioMerieux, Inc. took a median 92 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 90 days.

Top product codes

Product codeDeviceSubmissions510(k) clearances
LONSystem, Test, Automated, Antimicrobial Susceptibility, Short Incubation119119
JSJCulture Media, Selective And Non-Differential1818
JSGCulture Media, Non-Selective And Non-Differential1313
JSHCulture Media, Non-Selective And Differential1212
MDBSystem, Blood Culturing1212
JSICulture Media, Selective And Differential1111
NGZSusceptibility Test Plate, Antifungal1010
JSFCulture Media, Single Biochemical Test77
JWYManual Antimicrobial Susceptibility Test Systems66
DAPFibrinogen And Fibrin Split Products, Antigen, Antiserum, Control44

Plus 38 more product codes.

Review panels

Most recent bioMerieux, Inc. 510(k) clearances

510(k)DeviceProduct codeDecision dateReview days
K262807VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 – >=16µg/mL)LON2026-11-0489
K262683VITEK PROLON2026-11-0395
K260283VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)LON2026-10-01245
K260619VITEK 2 AST-Streptococcus Cefepime (<=0.06 – >=4 µg/mL)LON2026-09-28215
K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystemSAN2026-07-08169
K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistanceLON2026-04-1576
K260281VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)LON2026-03-2656
K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)LON2025-08-2190
K250856ETEST Aztreonam/Avibactam (AZA) (0.016/4-256/4 µg/mL)JWY2025-06-1283
K234012VITEK COMPACT PROLON2025-03-14451

251 earlier clearances. See the full list in Caduvo.

PMA and De Novo decisions

NumberPathwayDeviceDecision date
DEN130013De NovoSystem, Mass Spectrometry, Maldi Tof, Microorganism Identification, Cultured Isolates2013-08-21
P120014PMABIOMERIEUX THXID BRAF ASSAY KIT2013-05-29
P080008PMAVIDAS FREE PSA RT ASSAY2009-10-08
P040008PMAVIDAS TPSA ASSAY2004-07-08

Recalls

589 product recalls in 95 recall events; 106 initiated in the last five years. Most recent: 2026-07-24.

4 product recalls in 4 recall events filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 0 initiated in the last five years. Most often: BioMerieux SA (3), Biomerieux France Chemin De L'Or (1).

These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.

Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.

Device clinical trials

An industry sponsor named bioMerieux, Inc. is the lead sponsor of 3 device studies on ClinicalTrials.gov (0 active or recruiting). Most recent:

FDA spellings included

FDA records this applicant under 6 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:

Other FDA applicant names starting with the same word

FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.

Frequently asked questions

How many FDA 510(k) clearances are listed under bioMerieux, Inc.?

FDA lists 261 510(k) clearances under 6 spellings of the applicant name “bioMerieux, Inc.” (first 1983, latest 2026), plus 3 PMA and 1 De Novo decisions, across 48 product codes in 5 review panels. Filings under other applicant names, such as subsidiaries, are not included.

How long has FDA taken to clear 510(k)s filed by bioMerieux, Inc.?

The median time from FDA receipt to decision across 510(k)s cleared under the name bioMerieux, Inc. is 60 days. Since 2017: 92 days, versus 90 days for all cleared 510(k)s in the same product codes.

Which FDA product codes appear under bioMerieux, Inc.?

The most frequent FDA product codes under this applicant name are LON (System, Test, Automated, Antimicrobial Susceptibility, Short Incubation, 119); JSJ (Culture Media, Selective And Non-Differential, 18); JSG (Culture Media, Non-Selective And Non-Differential, 13).

Next steps

Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.

All FDA device companies · FDA product code lookup